Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Poor-Prognosis IgA Nephropathy
NCT00396721Phase 2Completed
- Start
- Jan 2006
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in IgA nephropathy (IgAN) (2 arms). Primary endpoint: Clinical composite variable (proteinuria, blood pressure, hematuria) at 12 months. Started Jan 2006; status: completed.
02
Drugs
sirolimus
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT00396721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396721.